Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
出版年份 2021 全文链接
标题
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
作者
关键词
-
出版物
Gastric Cancer
Volume 24, Issue 3, Pages 721-730
出版商
Springer Science and Business Media LLC
发表日期
2021-03-23
DOI
10.1007/s10120-020-01153-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- (2018) Ugur Sahin et al. EUROPEAN JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
- (2018) K Muro et al. ANNALS OF ONCOLOGY
- Characterization of zolbetuximab in pancreatic cancer models
- (2018) Ӧzlem Türeci et al. OncoImmunology
- Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
- (2017) A. Carmona-Bayonas et al. Gastric Cancer
- It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma
- (2017) Elena Elimova et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases
- (2017) Srinivas Raman et al. QUALITY OF LIFE RESEARCH
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review
- (2016) Silvia Sommariva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- Clinical epidemiology of gastric cancer
- (2014) TL Ang et al. SINGAPORE MEDICAL JOURNAL
- Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients
- (2011) J. Maringwa et al. ANNALS OF ONCOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started